Literature DB >> 7489253

Sodium butyrate inhibits platelet-derived growth factor-induced proliferation of vascular smooth muscle cells.

K Ranganna1, T Joshi, F M Yatsu.   

Abstract

Sodium butyrate (SB), a naturally occurring short-chain fatty acid, was investigated for its therapeutic value as an antiproliferative agent for vascular smooth muscle cells (SMCs). At 5-mmol/L concentration, SB had no significant effect on rat SMC proliferation. However, at the same concentration, SB inhibited platelet-derived growth factor (PDGF)-AA-, -AB-, and -BB-induced proliferation of SMCs. Exposure of SMCs to PDGF-BB resulted in activation of receptor intrinsic tyrosine kinase activity and autophosphorylation of beta-PDGF-receptor (beta-PDGFR). The activated beta-PDGFR physically associated and phosphorylated signaling molecules such as ras-GTPase activating protein (GAP) and phospholipase C gamma (PLC gamma). SB, in the absence of PDGF-BB, caused neither beta-PDGFR tyrosine phosphorylation nor phosphorylation and association of GAP and PLC gamma with beta-PDGFR. PDGF-BB-enhanced activation of receptor intrinsic tyrosine kinase activity and autophosphorylation of tyrosine residues of beta-PDGFR were unaffected by SB irrespective of whether SMCs were preincubated with SB before exposure to PDGF-BB plus SB or incubated concomitantly with PDGF-BB plus SB. Likewise, phosphorylation and association of GAP and PLC gamma with PDGF-BB-activated beta-PDGFR were unaffected. In addition, SB did not block PDGF-BB-stimulated, PLC gamma-mediated production of inositol triphosphate. Similarly, PDGF-BB-induced beta-PDGFR degradation was unaffected when SMCs were exposed to PDGF-BB plus SB, and SB by itself had no influence on beta-PDGFR degradation. Unlike beta-PDGFR kinase activity, mitogen-activated protein kinase (MAP-kinase) activity was stimulated by SB by about 2.7-fold. Exposure of SMCs to PDGF-BB caused an approximately 11.4-fold increase in MAP-kinase activity and this increase in activity was not significantly affected when cells were coincubated with PDGF-BB and SB (10.3-fold). However, pretreatment of SMCs with SB for 30 minutes and subsequent incubation in PDGF-BB plus SB abolished most of the PDGF-BB-induced MAP-kinase activity (4.6-fold). Transcription of growth response genes such as c-fos, c-jun, and c-myc were induced by PDGF-BB, and their induction was suppressed, particularly c-myc, by incubating SMCs with PDGF-BB plus SB. Similarly, preincubation of cells with SB for 30 minutes and subsequent incubation in PDGF-BB plus SB diminished PDGF-BB-induced transcription of c-fos, c-jun, and c-myc. However, SB by itself had no significant effect on c-fos, c-jun, and c-myc transcription.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489253     DOI: 10.1161/01.atv.15.12.2273

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  11 in total

1.  Molecular Events as Targets of Anticancer Drug Therapy.

Authors:  Adorján Aszalós; Sándor Eckhardt
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

2.  Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.

Authors:  Omana P Mathew; Kasturi Ranganna; Frank M Yatsu
Journal:  Biomed Pharmacother       Date:  2010-12       Impact factor: 6.529

3.  Butyrate inhibits proliferation-induced proliferating cell nuclear antigen expression (PCNA) in rat vascular smooth muscle cells.

Authors:  K Ranganna; F M Yatsu; B E Hayes; S G Milton; A Jayakumar
Journal:  Mol Cell Biochem       Date:  2000-02       Impact factor: 3.396

4.  Acrolein activates mitogen-activated protein kinase signal transduction pathways in rat vascular smooth muscle cells.

Authors:  Kasturi Ranganna; Zivar Yousefipour; Rami Nasif; Frank M Yatsu; Shirlette G Milton; Barbara E Hayes
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

5.  Quiescence, cell viability, apoptosis and necrosis of smooth muscle cells using different growth inhibitors.

Authors:  J Pelisek; S Armeanu; S Nikol
Journal:  Cell Prolif       Date:  2001-10       Impact factor: 6.831

6.  Gene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation.

Authors:  Kasturi Ranganna; Zivar Yousefipour; Frank M Yatsu; Shirlette G Milton; Barbara E Hayes
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

Review 7.  Expression profiling of cardiovascular disease.

Authors:  Stephen Archacki; Qing Wang
Journal:  Hum Genomics       Date:  2004-08       Impact factor: 4.639

8.  Histone deacetylase inhibitors promote eNOS expression in vascular smooth muscle cells and suppress hypoxia-induced cell growth.

Authors:  Xiaoling Tan; Lan Feng; Xiaoyong Huang; Yidong Yang; Chengzhong Yang; Yuqi Gao
Journal:  J Cell Mol Med       Date:  2017-03-07       Impact factor: 5.310

9.  Butyrate-induced transcriptional changes in human colonic mucosa.

Authors:  Steven A L W Vanhoutvin; Freddy J Troost; Henrike M Hamer; Patrick J Lindsey; Ger H Koek; Daisy M A E Jonkers; Andrea Kodde; Koen Venema; Robert J M Brummer
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

10.  Vancomycin treatment and butyrate supplementation modulate gut microbe composition and severity of neointimal hyperplasia after arterial injury.

Authors:  Karen J Ho; Liqun Xiong; Nathaniel A Hubert; Anuradha Nadimpalli; Kelly Wun; Eugene B Chang; Melina R Kibbe
Journal:  Physiol Rep       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.